Omeros Corporation (LON:0KBU)

Market Cap	420.82M
Revenue (ttm)	n/a
Net Income (ttm)	-100.37M
Shares Out	n/a
EPS (ttm)	-1.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	216
Average Volume	1,691
Open	8.92
Previous Close	8.69
Day's Range	8.80 - 8.93
52-Week Range	2.09 - 10.85
Beta	n/a
RSI	53.96
Earnings Date	Feb 28, 2025

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunog...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1994
• Employees: 198
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0KBU

Financial Performance

Financial numbers in USD